{"id":1781,"date":"2025-02-03T08:59:16","date_gmt":"2025-02-03T08:59:16","guid":{"rendered":"https:\/\/www.merckvaccines.com\/capvaxive\/?page_id=1781"},"modified":"2026-03-26T08:26:48","modified_gmt":"2026-03-26T08:26:48","slug":"resources-for-your-practice","status":"publish","type":"page","link":"https:\/\/www.merckvaccines.com\/capvaxive\/resources-for-your-practice\/","title":{"rendered":"Resources for CAPVAXIVE\u00ae (Pneumococcal 21-valent Conjugate Vaccine) in Your Practice"},"content":{"rendered":"\n\n
<\/div>\n\n\n\n\n
\n\n

Resources for your practice<\/h1><\/div>\n\n\n\n
<\/div>\n\n\n\n

Your patients may ask you about this CAPVAXIVE commercial<\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n

Merck is running the following ad on television and online. Your patients may see it and ask you questions about CAPVAXIVE, or PCVs in general. Take a moment to watch the ad and prepare yourself for this very important discussion.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Learn more about CAPVAXIVE<\/strong><\/mark><\/a>, the only FDA-approved PCV that helps protect against serotypes responsible for ~82%<\/strong> of IPD cases in adults 50 years or older, compared to ~54%<\/strong> by PCV20 at a national level.1,2,a<\/sup><\/p>\n\n\n\n

<\/div>\n\n\n\n

These values are based on CDC epidemiologic data and do not reflect the efficacy of the respective vaccines.2<\/sup> There are currently no studies comparing the efficacy of CAPVAXIVE and PCV20. <\/p>\n\n\n\n

<\/div>\n<\/div><\/div><\/div>\n\n\n\n
\n\n